Loading the records…
Loading the records…
This $2.3B direct payment from CMS under Medicare Part D is a routine subsidy for prescription drug coverage distributed across multiple recipients, not a competitive contract. It carries no direct public company exposure and minimal stock-moving potential.
This award has no direct market implications for publicly traded stocks. Health insurers and pharmacy benefit managers already bake recurring Part D payments into earnings expectations. The absence of a named recipient and the subsidy classification mean no revenue surprise. Sector-wise, continued federal support for prescription drug coverage is a steady tailwind for healthcare, but not actionable from this single data point.
This contract award represents a $2.3B direct payment from the Centers for Medicare and Medicaid Services (CMS) under the Medicare Part D prescription drug coverage program. Unlike competitive procurement contracts, this is a subsidy or other non-reimbursable direct financial aid (contract type C), meaning funds are transferred to multiple recipients—likely including insurers, pharmacy benefit managers, and pharmacies—to offset the cost of providing prescription drug coverage to Medicare beneficiaries. No single publicly traded company is the named recipient, and the award is not tied to a specific corporate entity.
Because the recipient is listed as 'MULTIPLE RECIPIENTS' and the contract type is a subsidy, there is no direct public company beneficiary to analyze. While large health insurers (e.g., UnitedHealth Group, CVS Health) and pharmacy chains administer Part D plans, this payment is dispersed broadly and not attributable to any single firm. Attempting to assign a ticker would produce a false positive.
No related bills from the HillSignal database share a specific objective or funding mechanism with this contract. The only healthcare-related bill, S5006 'Work Without Worry Act of 2026', addresses workplace protections and does not intersect with Medicare Part D subsidies. Therefore, no legislative tailwind or headwind directly affects this award.
No supply chain partners or subcontractors are identifiable, as the payment is a direct subsidy with no competitive contracting process. Historical patterns show that Medicare Part D subsidies are recurring annual appropriations, with the total program spending exceeding $100B per year. This $2.3B award likely represents a partial disbursement of routine funding, not a new initiative.
For retail investors, this award has negligible direct market impact. The healthcare sector broadly benefits from sustained federal support for prescription drug coverage, but no specific company sees a material revenue change from this single subsidy payment.
Matched on shared policy language across AI analyses, with ticker & timing weight
MULTIPLE RECIPIENTS: $969M Department of Health and Human Services Federal Award
MULTIPLE RECIPIENTS: $669M Department of Health and Human Services Federal Award
MULTIPLE RECIPIENTS: $1.1B Department of Health and Human Services Federal Award
MULTIPLE RECIPIENTS: $6.8B Department of Health and Human Services Federal Award
Executive orders & memoranda affecting the same sectors or companies
This executive order requires all federal contractors and subcontractors to notify the White House and relevant agencies of any congressional requests related to their work with the executive branch, and to follow instructions to withhold information deemed protected by executive privilege. It directs agencies to enforce these requirements through contract termination or debarment, and tasks the Office of Management and Budget with developing implementation guidance. The order aims to protect executive branch confidentiality and enhance efficiency in federal contracting by preventing uncoordinated disclosures to Congress.
This executive order establishes a Women's Health Division within the NIH to coordinate and accelerate research on understudied women's health conditions, and creates a White House Women's Health Task Force to drive policy reforms and translation of research into clinical practice across federal agencies. It directs specific agencies to prioritize research, data collection, and translation into prevention, diagnosis, and treatment, with a focus on all life stages from infancy through aging.
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
Recipient
MULTIPLE RECIPIENTS
Award Amount
$2,300,087,407
Awarding Agency
Department of Health and Human Services
Sub-Agency
Centers for Medicare and Medicaid Services
Contract Type
DIRECT PAYMENT FOR SPECIFIED USE, AS A SUBSIDY OR OTHER NON-REIMBURSABLE DIRECT FINANCIAL AID (C)
Free — no credit card
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →